Lineage Cell Therapeutics Inc.

05/06/2024 | Press release | Distributed by Public on 05/06/2024 07:49

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit